Dicycloverine
 | |
| Clinical data | |
|---|---|
| Trade names | Byclomine, Bentyl, Dibent, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a684007 |
| License data |
|
| Pregnancy category |
|
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Protein binding | >99% |
| Elimination half-life | 5 h |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.000.919 |
| Chemical and physical data | |
| Formula | C19H35NO2 |
| Molar mass | 309.494 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Dicycloverine, also known as dicyclomine, sold under the brand name Bentyl among others, is a medication that is used to treat spasms of the intestines such as those that occur in irritable bowel syndrome.[1][2] It is taken by mouth or by injection into a muscle.[2] While it has been used in baby colic and enterocolitis, evidence does not support these uses.[2]
Common side effects include dry mouth, blurry vision, weakness, sleepiness, and lightheadedness.[2] Serious side effects may include psychosis and breathing problems in babies.[2] Use in pregnancy appears to be safe while use during breastfeeding is not recommended.[3] How it works is not entirely clear.[2]
Dicycloverine was approved for medical use in the United States in 1950.[2] It is available as a generic medication.[1] In 2022, it was the 176th most commonly prescribed medication in the United States, with more than 2 million prescriptions.[4][5]
Medical uses
[edit]Dicycloverine is used to treat the symptoms of irritable bowel syndrome, specifically hypermotility, in adults.[6][7] As of 2016, clinical guidelines recommended dicycloverine and other antispasmodics for IBS with diarrhea as a first line treatment.[6]
Anxiety
[edit]Dicyclomine can also be helpful for the treatment of Anxiety, but this is an off label use. [8]
Contraindications
[edit]This medicine should not be used for people who have an obstructive GI or urinary condition, severe ulcerative colitis, reflux, any unstable cardiac condition, glaucoma, myasthenia gravis, and anyone who is acutely bleeding.[7]
It should not be given to children or infants with colic due to the risks of convulsions, difficult breathing, irritability, and restlessness,[9] and there is little evidence to support the efficacy in such use in any case.[10]
Dicycloverine is known to impair thinking and coordination.[7]
The effect on the baby during pregnancy or breastfeeding is not well understood.[7]
Adverse effects
[edit]Dicycloverine can cause a range of anticholinergic side effects such as dry mouth, nausea, blurred vision, dizziness, confusion, severe constipation, stomach pain, heart palpitations, difficulty urinating, and seizures.[6]
Pharmacology
[edit]Pharmacodynamics
[edit]Dicycloverine is a selective muscarinic acetylcholine 1 receptor antagonist.[11] It blocks the action of acetylcholine on muscarinic receptors on smooth muscles in the gastrointestinal tract, relaxing the smooth muscle.[6]
History
[edit]
Dicycloverine was first synthesized chemically in the United States circa 1945 by scientists at William S. Merrell Company.[12]
It was first marketed in 1952 for gastrointestinal disorders, including colic in infants.[9] The INN name "dicycloverine" was recommended in 1959.[13] It was included in the combination drug for morning sickness called Bendectin, along with doxylamine and vitamin B6 which was launched in the US in 1956; dicycloverine was removed from the formulation in 1976 after Merrell determined that it added no value. Bendectin became the subject of many lawsuits due to allegations that it had caused birth defects similar to thalidomide, which Merrell had also marketed in the US and Canada.[14]
In the 1980s, several governments restricted its use in infants due to reports of convulsions, difficult breathing, irritability, and restlessness in infants given the drug.[9]
In 1994, the US Federal Trade Commission ordered Marion Merrell Dow, which had acquired Rugby Darby—the only generic manufacturer of dicycloverine in the US—to promise to grant licenses to its intellectual property on the drug to any company that wanted it, based on antitrust concerns. The US market for the medication at that time was around $8 million; Dow had 60% of it and Rugby had 40%. The next year, Hoechst Marion Roussel, which by that time had acquired the business, granted a license to Endo Pharmaceuticals. By 2000 several other generic competitors had started selling the medication. The case was part of the reshaping of the US pharmaceutical market that occurred in the 1990s, to favor generic entry.[15]
Society and culture
[edit]Rarely, there have been reports of dicycloverine abuse. Dicycloverine is an antagonist at σ1[16] and 5-HT2A[17] receptor sites, though its affinities for these targets are roughly one-fifth to one-tenth as strong as its affinities for CHRM1[18] and CHRM4[19] (its clinical targets). It is also a relatively non-polar tertiary amine, able to cross the blood–brain barrier, leading to delirium at high concentrations.[6][20]
References
[edit]- ^ a b British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 759. ISBN 9780857113382.
- ^ a b c d e f g "Dicyclomine Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.
- ^ "Dicyclomine Pregnancy and Breastfeeding Warnings". Drugs.com. Retrieved 3 March 2019.
- ^ "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
- ^ "Dicyclomine Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.
- ^ a b c d e Canadian Agency for Drugs and Technologies in Health (3 December 2015). "Dicyclomine for Gastrointestinal Conditions: A Review of the Clinical Effectiveness, Safety, and Guidelines". CADTH Rapid Response Reports. PMID 26985553.
- ^ a b c d AHFS Staff (2006). "Dicyclomine hydrochloride". AHFS DI Essentials. Bethesda, MD: American Society of Health-System Pharmacists / drugs.com. Retrieved 25 November 2018.
- ^ "Dicyclomine: A Potential Treatment for Anxiety". 12 March 2023.
- ^ a b c Consolidated List of Products Whose Consumption and/or Sale Have Been Banned, Withdrawn, Severely Restricted or Not Approved by Governments (PDF) (12 ed.). World Health Organization. 2005. p. 106. Archived from the original (PDF) on 7 April 2014. Retrieved 25 November 2018.
- ^ Biagioli E, Tarasco V, Lingua C, Moja L, Savino F (September 2016). "Pain-relieving agents for infantile colic". The Cochrane Database of Systematic Reviews. 2016 (9): CD009999. doi:10.1002/14651858.CD009999.pub2. hdl:2434/444531. PMC 6457752. PMID 27631535.
- ^ Giachetti A, Giraldo E, Ladinsky H, Montagna E (September 1986). "Binding and functional profiles of the selective M1 muscarinic receptor antagonists trihexyphenidyl and dicyclomine". Br J Pharmacol. 89 (1): 83–90. doi:10.1111/j.1476-5381.1986.tb11123.x. PMC 1917044. PMID 2432979.
- ^ "Dicyclomine". Pubchem. Retrieved 25 November 2018.
- ^ "International Nonproprietary Names for Pharmaceutical Preparations List #3" (PDF). WHO Chronicle. 13 (12): 463–474. December 1959. Retrieved 25 November 2018.
- ^ Sanders J (January 1992). "The Bendectin Litigation: A Case Study in the Life Cycle of Mass Torts" (PDF). Hastings Law Journal. 43 (2): 317. Retrieved 25 November 2018.
- ^ Chien C (2003). "Cheap Drugs at What Price to Innovation: Does the Compulsory Licensing of Pharmaceuticals Hurt Innovation?". Berkeley Technology Law Journal. 18 (3): 853–907. JSTOR 24116860.
- ^ "Bioactivity for AID 625223 - SID 103318016".
- ^ "Bioactivity for AID 625192 - SID 103318016".
- ^ "AID 625151 - DRUGMATRIX: Muscarinic M1 radioligand binding (Ligand: [3H] N-Methylscopolamine) - PubChem".
- ^ "AID 625154 - DRUGMATRIX: Muscarinic M4 radioligand binding (Ligand: [3H] N-Methylscopolamine) - PubChem".
- ^ Das S, Mondal S, Datta A, Bandyopadhyay S (September 2013). "A rare case of dicyclomine abuse". Journal of Young Pharmacists. 5 (3): 106–7. doi:10.1016/j.jyp.2013.08.004. PMC 3812884. PMID 24396252.
External links
[edit]
